Everyone's wrong about CRISPR therapies — the case for optimism

There's a temptation to treat this as a winner-take-all story. It probably isn't. The more durable advantage tends to accrue to the unglamorous middle layer — the tooling, the standards, the boring infrastructure that everything else quietly depends on.

None of this guarantees a happy ending. For every success there's a cautionary tale of capital torched and timelines blown. But the direction of travel is hard to argue with, and the people closest to CRISPR therapies are, if anything, more convinced than they were a year ago.

So where does that leave the rest of us? Watching the second-order effects, mostly. The first wave of any shift is loud and easy to see. The second — the one that actually reorganizes how work gets done — is slower, quieter, and far more consequential.

If you want a single signal to track, watch the people who have no incentive to hype it: regulators, insurers, procurement teams. When the skeptics start writing policy around CRISPR therapies, the conversation has already moved on.

It started, as these things often do, at the edges — a handful of teams, a few stubborn believers, and a thesis most people were happy to ignore. The interesting question was never whether CRISPR therapies would matter, but how quickly the rest of the world would notice.

The data tells a quieter story than the discourse. Adoption curves rarely move in straight lines; they stall, double back, and then surprise everyone with a sudden steepening. CRISPR therapies looks a lot like that — uneven, occasionally overhyped, and yet undeniably real.